在全球每年新增17万例多发性骨髓瘤患者的严峻形势下，CAR-T细胞疗法曾为复发难治患者带来曙光。但最新临床数据显示，接受BCMA靶向治疗的患者中，超过60%会在两年内出现抗原逃逸性复发。这种被称为'BCMA阴性复发'的现象，犹如悬在免疫治疗领域的达摩克利斯之剑，让医学界陷入新的困境。2025年3月，上海瑞金医院许捷团队在Molecular Therapy发表的突破性研究，不仅揭示了复发背后的分子机 ...

Researchers have discovered a type of "molecular glue" that can be used to inhibit certain pathological protein interactions.

A new therapy that first made headlines in 2021 is now showing potential to heal human cartilage. Developed by scientists at Northwestern University, the technique was initially created to repair ...

在多发性骨髓瘤（MM）的治疗中，CAR-T细胞免疫疗法无疑是一场革命。能持续获得治疗反应的患者，往往在治疗后却又要面临复发的困扰。根据瑞金医院血液科许捷团队在国际期刊Molecular Therapy上发表的最新研究，这其中涉及的复杂机制让人不得不重新审视CAR-T治疗的未来发展。到底是何原因导致了BCMA阴性的复发？通过细致的科研分析，许捷团队揭开了这一谜团！

1 Department of Medicine, University of California at Los Angeles, Los Angeles, California 2 Departments of Molecular Pharmacology and Urology, University of California at Los Angeles, Los Angeles ...

As a first step toward developing a therapy for FGR, Guolin He, Xinghui Liu, and colleagues at West China Second University Hospital, Sichuan University, and Chongqing Medical University wanted to ...

Expert Rev Hematol. 2011;4(5):551-562. In addition, there are several trials currently examining the combination of bortezomib and histone deacetylase inhibitors (HDACi) or 5-azacitidine in the ...

CAR T-cell therapy showed encouraging efficacy and good safety in newly diagnosed Ph-positive ALL,” the researchers wrote.

Molecular Partners AG’s MOLN share price has surged by 5.04%, which has investors questioning if this is right time to sell.

Moreover, the panelists emphasized that real-world evidence goes beyond clinical trial data. It involves continuous patient ...